ATE279442T1 - Humanisierte antikörper, die amyloid beta peptid sequestrieren - Google Patents

Humanisierte antikörper, die amyloid beta peptid sequestrieren

Info

Publication number
ATE279442T1
ATE279442T1 AT01913081T AT01913081T ATE279442T1 AT E279442 T1 ATE279442 T1 AT E279442T1 AT 01913081 T AT01913081 T AT 01913081T AT 01913081 T AT01913081 T AT 01913081T AT E279442 T1 ATE279442 T1 AT E279442T1
Authority
AT
Austria
Prior art keywords
humanized antibodies
amyloid beta
sequestring
beta peptide
peptide
Prior art date
Application number
AT01913081T
Other languages
German (de)
English (en)
Inventor
David M Holtzman
Ronald Demattos
Kelly R Bales
Steven M Paul
Naoya Tsurushita
Maximiliano Vasquez
Original Assignee
Univ St Louis
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27391859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE279442(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ St Louis, Lilly Co Eli filed Critical Univ St Louis
Application granted granted Critical
Publication of ATE279442T1 publication Critical patent/ATE279442T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01913081T 2000-02-24 2001-02-26 Humanisierte antikörper, die amyloid beta peptid sequestrieren ATE279442T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18460100P 2000-02-24 2000-02-24
US25449800P 2000-12-08 2000-12-08
US25446500P 2000-12-08 2000-12-08
PCT/US2001/006191 WO2001062801A2 (en) 2000-02-24 2001-02-26 Humanized antibodies that sequester amyloid beta peptide

Publications (1)

Publication Number Publication Date
ATE279442T1 true ATE279442T1 (de) 2004-10-15

Family

ID=27391859

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01913081T ATE279442T1 (de) 2000-02-24 2001-02-26 Humanisierte antikörper, die amyloid beta peptid sequestrieren

Country Status (32)

Country Link
US (4) US7195761B2 (enExample)
EP (4) EP1481992B1 (enExample)
JP (2) JP4738696B2 (enExample)
KR (1) KR100767146B1 (enExample)
CN (3) CN101670105B (enExample)
AT (1) ATE279442T1 (enExample)
AU (1) AU4178601A (enExample)
BR (1) BRPI0108676B8 (enExample)
CA (1) CA2400559C (enExample)
CY (1) CY1118381T1 (enExample)
CZ (2) CZ304211B6 (enExample)
DE (2) DE60106394T3 (enExample)
DK (2) DK1257584T4 (enExample)
DZ (1) DZ3295A1 (enExample)
EA (1) EA006606B1 (enExample)
ES (2) ES2184660T5 (enExample)
HK (1) HK1048640B (enExample)
HR (2) HRP20080430B1 (enExample)
HU (2) HUP0204074A3 (enExample)
IL (3) IL151378A0 (enExample)
LT (1) LT1481992T (enExample)
MX (1) MXPA02008145A (enExample)
NO (2) NO329840B1 (enExample)
NZ (1) NZ520800A (enExample)
PL (2) PL218883B1 (enExample)
PT (2) PT1257584E (enExample)
SI (2) SI1257584T2 (enExample)
SK (2) SK288711B6 (enExample)
TR (1) TR200202799T3 (enExample)
UA (1) UA75881C2 (enExample)
WO (1) WO2001062801A2 (enExample)
ZA (1) ZA200206712B (enExample)

Families Citing this family (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
ATE405636T1 (de) 1999-06-16 2008-09-15 Boston Biomedical Res Inst Immunologische kontrolle des beta-amyloid gehaltes in vivo
SK288711B6 (sk) 2000-02-24 2019-11-05 Univ Washington Humanizovaná protilátka, jej fragment a ich použitie, polynukleová kyselina, expresný vektor, bunka a farmaceutický prostriedok
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
EP1385545B1 (en) * 2001-04-30 2009-01-07 Eli Lilly And Company Humanized antibodies recognizing the beta-amyloid peptide
EP1385544B1 (en) * 2001-04-30 2008-09-24 Eli Lilly And Company Humanized antibodies
US20020197258A1 (en) * 2001-06-22 2002-12-26 Ghanbari Hossein A. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
WO2003014162A1 (en) † 2001-08-03 2003-02-20 Medical & Biological Laboratories Co., Ltd. ANTIBODY RECOGNIZING GM1 GANGLIOSIDE-BOUND AMYLOID β-PROTEIN AND DNA ENCODING THE ANTIBODY
EP1432444A4 (en) * 2001-08-17 2005-11-02 Lilly Co Eli ANTI-BETA ANTIBODIES
JP2005500389A (ja) * 2001-08-17 2005-01-06 イーライ・リリー・アンド・カンパニー Ａβに関連する病態および疾患を治療するための、可溶性Ａβに高い親和性を有する抗体の使用
AU2002324468A1 (en) * 2001-08-17 2003-03-03 Eli Lilly And Company Rapid improvement of cognition in conditions related to abeta
PT1416965E (pt) * 2001-08-17 2008-04-01 Lilly Co Eli Método de ensaio para a doença de alzheimer
PT1944040E (pt) 2001-08-17 2012-10-31 Univ Washington Método de avaliação para a doença de alzheimer
US7179606B2 (en) * 2001-11-23 2007-02-20 Syn X Pharma, Inc. IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
ATE419871T1 (de) * 2002-04-25 2009-01-15 Lilly Co Eli Verfahren zur behandlung von angststörungen bei älteren personen
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
FR2846667B1 (fr) * 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
WO2004056318A2 (en) 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1594969B1 (en) * 2003-02-01 2015-05-20 Janssen Sciences Ireland UC Active immunization to generate antibodies to soluble a-beta
US7575747B2 (en) 2003-02-10 2009-08-18 Applied Molecular Evolution Aβ binding molecules
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
TWI306458B (en) * 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US7736644B2 (en) 2003-06-27 2010-06-15 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
KR101139103B1 (ko) * 2003-09-12 2012-07-05 아피리스 아게 아페레시스 장치
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US7848543B2 (en) * 2004-02-05 2010-12-07 Brainlab Ag Method and system for prediction and management of material and information transport in an organism
US20070190046A1 (en) * 2004-02-23 2007-08-16 Eli Lilly And Company Anti-abeta antibody
WO2005105998A1 (ja) * 2004-04-27 2005-11-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント
EP1769002A1 (en) * 2004-07-02 2007-04-04 Northwestern University Monolocal antibodies that target pathological assemblies of amyloid beta; (abeta)
US20060024667A1 (en) 2004-07-29 2006-02-02 Karen Manucharyan Compositions and methods for Alzheimer's disease
JP2008515438A (ja) * 2004-10-05 2008-05-15 ワイス 組換えタンパク質産生の改善方法および組成物
US9901413B2 (en) * 2004-10-15 2018-02-27 Brainlab Ag Targeted infusion of agents for treatment of ALS
US9924888B2 (en) * 2004-10-15 2018-03-27 Brainlab Ag Targeted infusion of agents against parkinson's disease
US9907485B2 (en) * 2004-10-15 2018-03-06 Brainlab Ag Targeted immunization and plaque destruction against Alzheimer's disease
CA2589017A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Amyloid beta antibodies for use in improving cognition
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
WO2006066049A2 (en) * 2004-12-15 2006-06-22 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
EP1827493A4 (en) * 2004-12-22 2009-09-30 Univ St Louis USE OF ANTI-ABETA ANTIBODIES FOR THE TREATMENT OF BRAIN TRAUMA
WO2006081171A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EP1896504B1 (en) 2005-06-17 2012-11-21 Wyeth LLC Methods of purifying fc region containing antibodies
PT2289909E (pt) 2005-11-30 2015-02-10 Abbvie Inc Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos
PL1976877T5 (pl) * 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
EP2808032B1 (en) 2005-12-12 2018-08-01 AC Immune S.A. A beta 1-42 specific monoclonal antibodies with therapeutic properties
DOP2006000278A (es) 2005-12-12 2007-07-15 Hoffmann La Roche Glicosilación en la región variable
KR20120093400A (ko) * 2006-03-30 2012-08-22 글락소 그룹 리미티드 아밀로이드?베타 펩티드에 대한 항체
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN101058608B (zh) * 2006-04-21 2011-02-23 杜如昱 人类抗Aβ1-32淀粉样蛋白抗体、其纯化方法及用途
EP3988566A1 (en) * 2006-07-14 2022-04-27 AC Immune SA Humanized antibody against amyloid beta
CL2007002070A1 (es) 2006-07-14 2008-02-08 Ac Immune S A Genentech Inc Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade
KR20160049045A (ko) * 2006-07-14 2016-05-04 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
NO348280B1 (no) * 2006-07-14 2024-11-04 Genentech Inc Humanisert antistoff
ES2640095T3 (es) * 2006-10-02 2017-10-31 Ac Immune S.A. Anticuerpo humanizado contra beta-amiloide
AU2007308145A1 (en) 2006-10-12 2008-04-17 Wyeth Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
SI2104682T1 (sl) 2007-01-11 2017-05-31 Michael Bacher Diagnostika in zdravljenje Alzheimerjeve bolezni in drugih nevrodementnih bolezni
ES2615454T3 (es) 2007-01-18 2017-06-07 Eli Lilly And Company Fab pegilado contra el amiloide beta
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EA200901140A1 (ru) 2007-03-01 2010-04-30 Пробиодруг Аг Новое применение ингибиторов глутаминилциклазы
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP2011526240A (ja) * 2007-04-18 2011-10-06 ヤンセン アルツハイマー イミュノセラピー 脳アミロイド血管症の予防および治療
WO2008144232A2 (en) 2007-05-18 2008-11-27 The Johns Hopkins University A treatment simulator for brain diseases and method of use thereof
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
JP2010528583A (ja) * 2007-06-11 2010-08-26 エーシー イミューン ソシエテ アノニム アミロイドβに対するヒト化抗体
CN101820911B (zh) * 2007-06-12 2015-05-06 Ac免疫有限公司 β淀粉样蛋白的人源化抗体
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
CN101842388B (zh) * 2007-09-13 2013-09-04 德勒尼克斯治疗股份公司 针对β淀粉样肽的人源化抗体
RU2604181C2 (ru) 2007-10-05 2016-12-10 Дженентек, Инк. Применение антитела против амилоида бета при глазных заболеваниях
WO2009048537A2 (en) * 2007-10-05 2009-04-16 Genentech, Inc. Humanized antibody
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
DK2207568T3 (en) * 2007-11-16 2017-09-18 Univ Rockefeller ANTIBODIES SPECIFIC TO THE PROTOFIBRILE FORM OF BETA AMYLOID PROTEIN
EP2261254A3 (en) 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
EP2106802A1 (en) 2008-04-02 2009-10-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Modified peptides as synthetic vaccines in amyloid-associated disease
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
US8815794B2 (en) 2008-08-28 2014-08-26 The Research Foundation For The State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8614297B2 (en) 2008-12-22 2013-12-24 Hoffmann-La Roche Inc. Anti-idiotype antibody against an antibody against the amyloid β peptide
CN102695546B (zh) 2009-09-11 2014-09-10 前体生物药物股份公司 作为谷氨酰胺酰环化酶抑制剂的杂环衍生物
BR112012014060B8 (pt) 2009-12-11 2021-07-27 Araclon Biotech Sl método para o diagnóstico da doença de alzheimer em um sujeito, para detecção da disfunção cognitiva branda ou para diferenciar a doença de alzheimer da disfunção cognitiva branda
WO2011109246A1 (en) 2010-03-01 2011-09-09 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
SG183229A1 (en) 2010-03-10 2012-09-27 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2011149461A1 (en) 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
WO2012016173A2 (en) 2010-07-30 2012-02-02 Ac Immune S.A. Safe and functional humanized antibodies
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
SI3590949T1 (sl) 2010-10-01 2022-09-30 Modernatx, Inc. Ribonukleinske kisline, ki vsebujejo N1-metil-psevdouracil, in njihove uporabe
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
WO2013030713A1 (en) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
JP2012050437A (ja) * 2011-09-12 2012-03-15 Janssen Alzheimer Immunotherapy ベータアミロイドペプチドを認識するヒト化抗体
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
RU2649364C2 (ru) 2011-12-16 2018-04-02 Модерна Терапьютикс, Инк. Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
US9963511B2 (en) * 2011-12-22 2018-05-08 Hoffmann-La Roche Inc. Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
EP3520821A1 (en) 2012-04-02 2019-08-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2872154C (en) 2012-05-04 2016-08-23 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2
MD20140130A2 (ro) 2012-06-29 2015-04-30 Pfizer Inc. 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
BR112014033066A2 (pt) * 2012-07-03 2017-08-01 Janssen Alzheimer Immunotherap método para tratamento de um paciente diagnosticado com doença de alzheimer, forma humanizada, quimérica ou revestida de um anticorpo, e, anticorpo.
WO2014045162A1 (en) 2012-09-20 2014-03-27 Pfizer Inc. ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-ANIME COMPOUNDS
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
SI2922554T1 (sl) 2012-11-26 2022-06-30 Modernatx, Inc. Terminalno modificirana RNA
EP2931731A1 (en) 2012-12-11 2015-10-21 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
JP6162820B2 (ja) 2012-12-19 2017-07-12 ファイザー・インク 炭素環式および複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2014125394A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EA201591360A1 (ru) 2013-02-19 2016-03-31 Пфайзер Инк. Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
AR096364A1 (es) 2013-05-20 2015-12-23 Genentech Inc Anticuerpos receptores de antitransferina y métodos de uso
MX2016002799A (es) 2013-09-13 2016-05-26 Genentech Inc Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
WO2015038888A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Methods and compositions comprising purified recombinant polypeptides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
JP6425717B2 (ja) 2013-10-04 2018-11-21 ファイザー・インク ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
CR20160454A (es) 2014-04-01 2016-12-06 Pfizer CROMENO Y 1,1 a,2,7b—TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS
AU2015245260A1 (en) 2014-04-10 2016-10-06 Pfizer Inc. 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
AU2015298378B2 (en) 2014-08-06 2018-08-02 Pfizer Inc. Imidazopyridazine compounds
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
HRP20210124T1 (hr) 2014-11-19 2021-03-19 Axon Neuroscience Se Humanizirana tau antitijela u alzheimerovoj bolesti
DK3253755T3 (da) 2015-02-03 2020-09-28 Pfizer Hidtil ukendte cyclopropabenzofuranyl-pyridopyrazindioner
TN2017000485A1 (en) 2015-06-17 2019-04-12 Pfizer Tricyclic compounds and their use as phosphodiesterase inhibitors
CA2991856A1 (en) * 2015-07-21 2017-01-26 Bioarctic Neuroscience Ab Method for treatment of traumatic brain injury targeting aggregated peptides
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
AU2016325665A1 (en) 2015-09-24 2018-03-08 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
EP3353174A1 (en) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN116196410A (zh) 2015-10-28 2023-06-02 宾夕法尼亚州大学信托人 鞘内施用腺伴随病毒载体用于基因治疗
CN108350052A (zh) * 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中间区域中的表位及其构象选择性抗体
EP3374379A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATION-SELECTIVE ANTIBODIES
JP7452829B2 (ja) 2015-11-09 2024-03-19 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータのエピトープおよびそれに対する抗体
CN108699080B (zh) 2016-02-23 2021-05-14 辉瑞公司 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物
SG11201811712QA (en) 2016-07-01 2019-01-30 Pfizer 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
WO2018014126A1 (en) 2016-07-18 2018-01-25 The University Of British Columbia Antibodies to amyloid beta
EP3496750A2 (en) * 2016-08-09 2019-06-19 Eli Lilly and Company Combination therapy
US20200055917A1 (en) 2016-09-27 2020-02-20 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules
CA3042236A1 (en) * 2016-10-28 2018-05-03 Washington University Anti-apoe antibodies
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
EP3592740B1 (en) 2017-03-10 2022-02-09 Pfizer Inc. Cyclic substituted imidazo[4,5-c]quinoline derivatives
EP3592741B1 (en) 2017-03-10 2023-02-15 Pfizer Inc. Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
US20230137562A1 (en) 2017-06-07 2023-05-04 Adrx, Inc. Tau aggregation inhibitors
FI3642202T3 (fi) 2017-06-22 2023-03-01 Dihydro-pyrrolo-pyridiinijohdannaisia
AU2018290898B2 (en) * 2017-06-29 2021-03-11 The Trustees Of Columbia University In The City Of New York Chimeric antibodies for treatment of amyloid deposition diseases
CA3070085A1 (en) 2017-07-18 2019-01-24 Promis Neurosciences Inc. Antibodies to amyloid beta
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
US12227567B2 (en) 2017-07-25 2025-02-18 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
US11453701B2 (en) 2017-08-18 2022-09-27 Adrx, Inc. Tau aggregation peptide inhibitors
WO2019067328A1 (en) 2017-09-26 2019-04-04 Cero Therapeutics, Inc. CHIMERIC ENGINEERING RECEPTOR MOLECULES AND METHODS OF USE
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
WO2019074840A1 (en) * 2017-10-09 2019-04-18 Keith Black COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOID RELATED DISEASES
WO2019183636A1 (en) 2018-03-23 2019-09-26 Pfizer Inc. Piperazine azaspiro derivaves
JP7444781B2 (ja) 2018-03-28 2024-03-06 セロ・セラピューティクス・インコーポレイテッド 細胞免疫療法組成物およびその使用
WO2019191332A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
US20210309726A1 (en) * 2018-05-21 2021-10-07 New York University Treatment of melanoma brain metastasis by inhibition of amyloid precursor protein cleavage
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
CA3115071A1 (en) 2018-10-04 2020-04-09 University Of Rochester Improvement of glymphatic delivery by manipulating plasma osmolarity
WO2020132230A2 (en) 2018-12-20 2020-06-25 Genentech, Inc. Modified antibody fcs and methods of use
FR3091999A1 (fr) * 2019-01-25 2020-07-31 Mexbrain Dispositif d’extraction conjointe d’un cation métallique et d’une molécule cible
WO2021076620A1 (en) 2019-10-15 2021-04-22 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CA3185040A1 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
BR112023001061A2 (pt) 2020-07-23 2023-04-04 Othair Prothena Ltd Anticorpos antiabeta
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022182658A1 (en) 2021-02-23 2022-09-01 Hoth Therapeutics, Inc. Use of aprepitant for treating alzheimer's disease
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2023150483A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease
WO2025032070A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Anti-a-beta protein antibodies, methods and uses thereof
WO2025145091A1 (en) 2023-12-29 2025-07-03 Pfizer Inc. Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5278049A (en) * 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
FR2608669A1 (fr) 1986-12-19 1988-06-24 Boussois Sa Vitrage pret a sa pose et son procede de fabrication et de fixation
US4933156A (en) * 1987-04-08 1990-06-12 Salutar, Inc. Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
EP0667959B1 (en) * 1992-10-26 2003-08-13 Elan Pharmaceuticals, Inc. Methods for identifying inhibitors of the production of beta-amyloid peptide
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
CN1136327A (zh) * 1993-09-28 1996-11-20 综合医院公司 用反义寡核苷酸调节神经生长并使β/A4淀粉样肽诱导的形态逆转
JPH09511492A (ja) 1994-02-03 1997-11-18 ザ ピコワー インスティテュート フォア メディカル リサーチ アミロイドーシスの前進性グリコシル化終末産物仲介モジュレーション用組成物及び方法
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20020086847A1 (en) 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
AU743827B2 (en) 1997-04-09 2002-02-07 Intellect Neurosciences, Inc. Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US6787319B2 (en) 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
EP0996736A1 (en) 1997-08-11 2000-05-03 Chiron Corporation Methods for genetically modifying t cells
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
CA2325600A1 (en) 1998-05-21 1999-11-25 The University Of Tennessee Research Corporation Methods for amyloid removal using anti-amyloid antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
ATE405636T1 (de) 1999-06-16 2008-09-15 Boston Biomedical Res Inst Immunologische kontrolle des beta-amyloid gehaltes in vivo
CA2381323C (en) 1999-08-04 2009-10-06 University Of Southern California Amyloid .beta. protein (globular assembly and uses thereof)
CA2349434A1 (en) 1999-09-03 2001-03-15 Ramot University Authority For Applied Research & Industrial Development Ltd. Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
SK288711B6 (sk) 2000-02-24 2019-11-05 Univ Washington Humanizovaná protilátka, jej fragment a ich použitie, polynukleová kyselina, expresný vektor, bunka a farmaceutický prostriedok
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
EP2067863A3 (en) 2000-09-06 2013-11-06 Aventis Pharma S.A. Methods and compositions for diseases associated with amyloidosis
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
PT1416965E (pt) 2001-08-17 2008-04-01 Lilly Co Eli Método de ensaio para a doença de alzheimer

Also Published As

Publication number Publication date
IL193631A0 (en) 2009-02-11
DE60106394D1 (de) 2004-11-18
NO20023957L (no) 2002-10-22
NO20023957D0 (no) 2002-08-20
PT1257584E (pt) 2005-01-31
NZ520800A (en) 2004-04-30
SI1257584T1 (en) 2005-04-30
IL193631A (en) 2010-11-30
PL210157B1 (pl) 2011-12-30
CA2400559A1 (en) 2001-08-30
JP4914412B2 (ja) 2012-04-11
EP3150633A1 (en) 2017-04-05
EA200200897A1 (ru) 2003-02-27
EP1481992A3 (en) 2004-12-08
US20090238821A1 (en) 2009-09-24
US20040043418A1 (en) 2004-03-04
CN1426423A (zh) 2003-06-25
PT1481992T (pt) 2017-01-02
HRP20080430A9 (en) 2009-02-28
CZ304211B6 (cs) 2014-01-08
ZA200206712B (en) 2003-11-21
DK1257584T4 (da) 2013-03-25
IL151378A0 (en) 2003-04-10
SK12212002A3 (sk) 2003-10-07
NO20083805L (no) 2002-10-22
EP1257584A2 (en) 2002-11-20
DK1257584T3 (da) 2005-01-17
JP4738696B2 (ja) 2011-08-03
NO337363B1 (no) 2016-03-29
HK1048640A1 (en) 2003-04-11
JP2003523764A (ja) 2003-08-12
UA75881C2 (en) 2006-06-15
EP1481992A2 (en) 2004-12-01
BRPI0108676B8 (pt) 2021-05-25
MXPA02008145A (es) 2004-04-05
SI1481992T1 (sl) 2017-01-31
BRPI0108676B1 (pt) 2015-09-15
ES2184660T5 (es) 2013-05-09
CY1118381T1 (el) 2017-06-28
HUP0800571A2 (en) 2003-03-28
CN1426423B (zh) 2010-05-12
HRP20080430B1 (hr) 2016-12-16
TR200202799T3 (tr) 2003-03-21
SK288711B6 (sk) 2019-11-05
NO329840B1 (no) 2011-01-10
CZ2008595A3 (cs) 2017-05-03
DE1257584T1 (de) 2003-05-28
HRP20020693A2 (en) 2004-12-31
EA006606B1 (ru) 2006-02-24
DE60106394T2 (de) 2006-03-09
SK288723B6 (sk) 2020-01-07
EP1257584B9 (en) 2004-12-01
CN101670105B (zh) 2014-08-06
CA2400559C (en) 2012-05-01
BR0108676A (pt) 2003-01-07
EP3070100A1 (en) 2016-09-21
DE60106394T3 (de) 2013-07-25
HUP0204074A2 (hu) 2003-03-28
DZ3295A1 (fr) 2001-08-30
CN104341500A (zh) 2015-02-11
JP2009046497A (ja) 2009-03-05
US20060039906A1 (en) 2006-02-23
EP1257584B1 (en) 2004-10-13
CZ20022851A3 (cs) 2003-09-17
DK1481992T3 (en) 2017-01-30
EP1481992B1 (en) 2016-11-02
US8591894B2 (en) 2013-11-26
CN101670105A (zh) 2010-03-17
US20110158986A1 (en) 2011-06-30
KR100767146B1 (ko) 2007-10-15
LT1481992T (lt) 2017-02-10
WO2001062801A2 (en) 2001-08-30
EP3070100B1 (en) 2021-07-07
SI1257584T2 (sl) 2013-07-31
HUP0204074A3 (en) 2004-07-28
US7195761B2 (en) 2007-03-27
PL218883B1 (pl) 2015-02-27
CZ306683B6 (cs) 2017-05-03
ES2184660T1 (es) 2003-04-16
IL151378A (en) 2010-04-29
HRP20020693B1 (hr) 2012-01-31
ES2611427T3 (es) 2017-05-08
WO2001062801A3 (en) 2002-01-31
US7892545B2 (en) 2011-02-22
HRP20080430A2 (en) 2008-11-30
ES2184660T3 (es) 2005-05-01
HK1048640B (en) 2005-04-01
AU4178601A (en) 2001-09-03
KR20020089359A (ko) 2002-11-29
PL356798A1 (en) 2004-07-12
HU230768B1 (hu) 2018-03-28
EP1257584B2 (en) 2013-03-06

Similar Documents

Publication Publication Date Title
ATE279442T1 (de) Humanisierte antikörper, die amyloid beta peptid sequestrieren
EA200602015A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
GEP20115195B (en) Antibodies directed against amyloid-beta peptide and use thereof
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
CY1110783T1 (el) Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
EP1613347A4 (en) BETA AMYLOID PEPTIDE DETECTING HUMANIZED ANTIBODIES
WO2003016467A3 (en) Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
GB0008305D0 (en) Treatment of fungal infections
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
ATE314861T1 (de) Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle
UA89028C2 (ru) Применение гуманизированного антитела, которое специфически связывает эпитоп, который находится между положениями 13 и 28 бета-амилоидного пептида для изготовления лекарственного средства для предотвращения или лечения предклинической или клинической формы болезни альцгеймера

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1257584

Country of ref document: EP